The Personnel-Hours Question in Psychedelic Therapy

For payers and analysts, the practical cost unit in psychedelic therapy is supervised human time. Preparation, dosing support, monitoring, integration, medical oversight, crisis planning, documentation, and follow-up all require staff. The drug may be clinically distinctive, but access often depends on how much scarce professional labour the protocol needs.

What the staff-hours model answers

This resource asks one recurring question: how many hours, delivered by which personnel, for how many patients? Clinical trials often report session counts, but reimbursement and capacity planning need a more operational measure: staff-hours per treated patient.

A one-session psychedelic treatment can sound operationally light until the full pathway is made visible. The patient may experience one dosing day, while the provider may need psychiatric screening, medication review, preparation visits, two clinicians in the room for most of a day, post-session observation, integration, documentation, supervision, and a return path into ordinary care.

The evidence map translates clinical protocols into service assumptions. First, what did the protocol ask staff to do? Second, how many staff-hours does that imply under individual, paired, or group delivery? Third, which hours must be delivered by scarce and expensive personnel in a given country, and which could safely shift to lower-cost roles under supervision?

Three measures are useful throughout. Patient-facing hours describe what the participant experiences. Staff-hours multiply that contact time by the number and type of staff present. System-hours add the surrounding work that is easy to miss in trial write-ups: prescribing, screening, documentation, training, supervision, facilities, adverse-event response, and programme coordination.

The formula is deliberately simple because it separates three layers. Session hours describe what the patient receives. Staff-hours describe what the service must staff. Total cost then adds role-specific wages, facilities, medicine cost, training, supervision, insurance, documentation, and payer overhead. A neutral model should keep those layers separate before making any affordability claim.

The care pathway

Modern psychedelic-assisted therapy protocols often follow a similar pathway even when the drug, indication, and therapeutic approach differ.

The pathway usually starts with screening and eligibility: psychiatric and medical history, contraindications, medication review, suicide and psychosis risk, consent, and treatment planning. Preparation builds trust, expectations, safety planning, and practical skills for difficult material. The dosing session is the most visible component, but integration and follow-up reconnect the experience to ordinary care through debriefing, behaviour change, outcome assessment, adverse-event review, and escalation if symptoms worsen.

For payers, this pathway matters because not every hour has the same cost or governance implication. For researchers, it matters because missing protocol details make later economic modelling fragile. A study that reports only "one dosing session" gives less implementation detail than a study that reports preparation time, acute staffing ratio, integration intensity, follow-up contacts, and who delivered each element.

Use the clinical-guidelines library alongside this model. The question of who can sit in the room is a clinical governance question as much as a cost question.

Evidence snapshot

The scan uses health-economic papers, trial records with structured preparation/dosing/integration fields, and clinical-guideline records. Together, they anchor protocol and competency assumptions before local service choices are added.

Representative health-economic papers

Representative trial-hour records

Representative clinical-guideline records

Protocol archetypes from the evidence base

These ranges are not treatment recommendations. They are working archetypes for reading the literature and turning protocols into comparable staff-hour models.

MDMA-assisted therapy for PTSD

Modern MDMA-assisted therapy is the high-hour archetype. The phase 3 therapeutic framework describes three 90-minute preparation sessions, two to three 8-hour experimental sessions, and repeated 90-minute integration sessions. With a two-therapist model, three 8-hour sessions alone can imply 48 staff-hours of acute-session coverage before preparation and integration are counted.

Psilocybin-assisted therapy for depression or TRD

Contemporary psilocybin therapy usually follows preparation, dosing, and integration. One mapping review summarises preparation as roughly 1-5 sessions or 2-8 hours, dosing as 1-3 sessions lasting 4-10 hours each, and integration as 2-8 sessions or 2-12 hours. Sloshower and colleagues provide a concrete ACT-framed example: two psilocybin dosing days, preparation before each, debriefing after each, and follow-up sessions, with about 16-20 therapy hours excluding the dosing days themselves.

Group-format psychedelic therapy

Group delivery has both historical and modern precedents. Older LSD studies used group formats, and the HOPE psilocybin cancer trial used group preparation, group dosing, and group integration, with one therapist per participant during dosing. Group therapy can reduce per-patient staff-hours when preparation and integration are shared, but the result depends on group size, dosing-session staffing, participant acuity, and whether individual sessions are still required. For a more explicit group and concurrent-care sensitivity model, see the group therapy economics resource.

Ketamine, esketamine, and shorter-acting models

Ketamine and esketamine models are useful comparators because repeated dosing and medical monitoring can dominate the time model even when psychotherapy is lighter or absent. Short-acting DMT or 5-MeO-DMT models could reduce acute-session coverage hours, but they do not remove screening, preparation, integration, prescribing, or risk-management work.

A staff-hours worksheet

For each protocol, a useful worksheet needs the same fields: compound and indication; evidence source; preparation sessions and duration; dosing sessions and duration; integration and follow-up; staffing ratio; patient-facing hours; staff-hours; and notes on medical oversight.

The worksheet is an audit trail, not a final price. It shows where the hours enter the model, which assumptions come from a trial protocol, and which assumptions are implementation choices. Two services can both call themselves psilocybin-assisted therapy while using different screening rules, preparation intensity, dosing-room staffing, and follow-up expectations.

Protocol-hours comparison

The point of the table is not to imply that one model is always better. It makes the bottleneck visible. MDMA-assisted therapy is dominated by long, highly staffed acute sessions; psilocybin models by full-day coverage and the surrounding therapy frame; group psilocybin by group size and dosing-room ratio; ketamine by repeated visits, medical monitoring, and clinic throughput.

For payers, the same clinical benefit can imply very different delivery constraints. A protocol with fewer dosing days may still be expensive if it requires senior clinicians before and after treatment. A protocol with shorter acute sessions may still be capacity-limited if repeated monitoring visits are needed. The table helps identify which part of the care model should be priced, staffed, or studied more carefully.

Which staff roles are actually needed?

Separate the personnel question into clinical accountability, therapeutic delivery, acute monitoring, and programme operations. One person may cover more than one role, but reimbursement and workforce planning should not hide those functions.

Personnel roles

"Therapist hours" is too blunt for reimbursement analysis. A psychiatrist hour, psychologist hour, nurse-monitoring hour, trained-facilitator hour, and programme-coordination hour can all be necessary, but they have different costs, scarcity constraints, professional rules, and substitution possibilities. A credible model identifies the function first, then asks which professional can safely and legally perform it in a specific system.

Why the same protocol costs different amounts by country

The hours may be similar across countries, but the cost and feasibility of those hours are not. The local question is which professional must perform or supervise each task, what that labour costs, and whether payers recognise the work.

Regional cost translation

Regional translation should start from the same staff-hour model and then change the local assumptions. Wage baselines, reimbursement logic, professional scope, and service setting can move the final estimate even when the clinical protocol is unchanged. The examples below are not legal summaries; they show how a payer or analyst might structure country-specific assumptions.

United States

In the United States, BLS wage data can anchor public wage assumptions for psychiatrists, psychologists, nurses, and social workers. Reimbursement modelling then has to translate wages into billed service prices, including clinic overhead, malpractice and compliance costs, coding assumptions, and product-specific risk management. The bottleneck is not only therapist time, but medical accountability, prescribing, emergency governance, and payer recognition of non-standard session lengths. FDA labels, REMS-like controls, CPT coding, and payer policies could materially change which hours are reimbursable.

United Kingdom

In the United Kingdom, NHS modelling should start with Agenda for Change bands for psychologists, nurses, therapists, and coordinators, plus medical pay scales for psychiatrists. A NICE-style assessment then weighs those staff-hours against cost per QALY, durability, service capacity, and comparators such as CBT, antidepressants, ECT, ketamine, or specialist PTSD care. The bottleneck is protected specialist time inside services that are already capacity-constrained. A future pathway could sit in ordinary mental-health services, specialist centres, research-linked clinics, or a mixed model.

Germany

Germany is a useful example for separating statutory reimbursement, physician involvement, psychotherapy provision, and clinic tariff logic. Public-sector labour assumptions can start from collective-pay tables, but statutory care, hospital tariffs, private psychotherapy, and specialist clinic delivery can produce different prices for the same staff-hour worksheet. The bottleneck is likely to sit around physician accountability, licensed psychotherapy provision, and whether acute-session support can be delegated.

Netherlands

For Dutch modelling, CAO GGZ 2025-2026 is the natural labour-cost baseline for mental-health institutions. Reimbursement would need to fit psychedelic therapy into specialist mental-health pathways rather than treating retreat availability as a proxy for reimbursable care. The bottleneck is likely to be GZ-psychologist, psychotherapist, psychiatrist, and specialist-nurse capacity inside an already stretched GGZ system.

Czech Republic

Czechia needs separate modelling because 2025 legislative changes and public statements point toward clinical psilocybin-assisted therapy introduction from 2026. Until mature reimbursement tariffs exist, labour assumptions depend on provider staffing, psychiatrist involvement, psychotherapist availability, and monitoring requirements. The bottleneck is pathway formation: which teams are authorised, what training is expected, and how psychotherapy requirements are specified.

What changes the model most?

The most important sensitivity analyses are concrete service-design choices: the number of dosing sessions, staffing ratio during acute sessions, individual support around group care, and durability of clinical benefit. These assumptions determine whether psychedelic therapy looks like a high-intensity specialist intervention for a narrow population or a model public systems could plausibly scale.

Moving from one to two or three acute sessions can dominate staff-hours. A two-therapist or 1:1 group dosing model changes cost more than small changes in preparation length. Group size can reduce per-patient preparation and integration hours, but only if safety, cohesion, and individual needs remain manageable. Personnel substitution may reduce cost only where regulation, evidence, supervision, and governance allow it.

What payers need before coverage modelling

Before coverage modelling, payers need more than an efficacy estimate. They need to understand the service that produced that estimate: staff mix, time requirements, monitoring obligations, retreatment expectations, adverse-event pathway, and comparator care displaced or added.

A payer-facing model should answer five questions. How many staff-hours are required per treated patient? Which hours require licensed specialists, and which can be delivered by other trained staff? How durable are benefits, and how often will patients need retreatment or stepped follow-up? Does group, hybrid, or stepped-care delivery preserve outcomes while changing the workforce bottleneck? What existing care does the intervention replace or add to?

Those questions do not settle coverage on their own. They make the budget-impact and capacity conversation explicit. A therapy can be clinically promising and still be difficult to commission if it depends on scarce staff in ways that ordinary session counts hide.

What to extract from trials and manuals

For researchers and analysts, the staff-hours question becomes an extraction discipline. Trial reports, protocols, manuals, and clinical guidelines should be read for operational details that can later support reimbursement, capacity, and implementation models.

The most useful fields are preparation sessions and duration; dosing or acute-support sessions and duration; integration sessions and duration; follow-up contacts; staff ratio during acute sessions; professional roles and supervision requirements; group size; individual support inside group models; adverse-event monitoring; dropout; retreatment; durability of benefit; and the comparator pathway. When those fields are missing, label the staff-hours estimate as an assumption rather than an evidence-derived value.

Explore the staff-hours model

Small protocol changes can move staff-hours more than the choice of country or wage source. The worksheet below keeps those assumptions visible: preparation intensity, number and length of dosing sessions, acute-session staffing, integration, group size, and blended labour cost. Read the output as a sensitivity check, not a tariff.

Care-pathway hours

The hours stack separates preparation, dosing support, integration, and shared sessions. An 8-hour dosing day is not 8 hours of system labour when two staff are present and pre/post work is counted.

Protocol comparison matrix

The protocol matrix places MDMA-assisted therapy, psilocybin-assisted therapy, group psilocybin, and ketamine-assisted psychotherapy on the same axis. The comparison is intentionally coarse: it shows where each model puts pressure on the workforce before local assumptions are added.

Staff-hours calculator

The calculator turns service design into a measure that can be priced. Staff-hours per treated patient is not the full cost of care, but it is the missing bridge between trial protocol and payer-facing budget impact.

Regional wage translator

The wage translator applies rough loaded staff-cost assumptions for the United States, United Kingdom, Netherlands, Germany, France, Spain, Italy, Czech Republic, and Sweden. It separates labour from medicine cost, facility overhead, training, supervision, and payer margin, so the output is not mistaken for a complete tariff.

Group-size sensitivity

The group-size slider shows where group delivery saves therapist time and where it does not. This avoids the overclaim that group therapy is automatically cheaper, while still showing why it may matter for workforce capacity.

Related implementation models

This page gives the base measure: staff-hours per treated patient. The group therapy economics model tests what changes when preparation, administration, integration, or follow-up are shared across patients. The payment-bundle model then asks how those hours, medicine costs, rooms, monitoring, registry work, and administrative overhead could become reimbursement objects.

Keeping the model useful

The durable layer is the care-phase model: screening, preparation, acute support, integration, follow-up, risk monitoring, and the distinction between patient-facing hours and staff-hours. Those categories should remain useful even as compounds, protocols, and reimbursement decisions change.

The updateable layers are protocol hours, role assumptions, wage baselines, country rules, clinical-guideline records, durability and retreatment assumptions, and payer interpretation. Keep evidence-derived protocol assumptions separate from stakeholder judgement, and date-stamp regional cost assumptions when they change.

Sources and update points

The evidence base draws on a preliminary review, Blossom trial and paper records, the clinical-guidelines library, and the external sources below. These links are the first places to check when protocol, wage, or regulatory assumptions change.

• Group therapy background: Trope et al. (2019), Psychedelic-Assisted Group Therapy: A Systematic Review.

• Modern group psilocybin example: Lewis et al. (2023), observations from the HOPE trial.

• MDMA therapy framework: O'Donnell et al. (2024), phase 3 therapeutic approach.

• Psilocybin therapy mapping: Kittur et al. (2025), therapeutic frameworks across contemporary trials.

• ACT psilocybin frame: Sloshower et al. (2019), psilocybin-assisted therapy using Acceptance and Commitment Therapy.

• Group delivery economics: Marseille et al. (2023), empirical estimates of cost savings and improved access.

• Blossom group-care model: Group Therapy Economics and Implementation.

• US wage baseline: Bureau of Labor Statistics occupational wage data, including OEWS tables.

• UK wage baseline: NHS Agenda for Change pay rates.

• Netherlands wage baseline: CAO GGZ 2025-2026.

• European labour-cost baseline: Eurostat hourly labour costs.

• Cross-country health-professional benchmark: OECD health professional remuneration dataset.

• Czech wage baseline: Czech Statistical Office healthcare personnel wages.

• Czech regulatory watch point: National Institute of Mental Health statement on psilocybin treatment availability.